VentureWell’s Post

The FDA has granted U.S. market authorization to Cepheid for the first rapid hepatitis C virus test that can be used in patient care settings and deliver results in about one hour. The new technology – validated through a collaboration between RADx Tech at The National Institutes of Health, FDA and Centers for Disease Control and Prevention – could help patients with positive tests begin treatment right away, rather than the current approach, which requires lengthy laboratory processing. Read more about this game changer for hepatitis C diagnosis: https://lnkd.in/gzeh_hQ8 #Hepatitis #MedTech #Diagnostics

".................The World Health Organization (#WHO) has released its 2023 Essential #Diagnostics List (#EDL), which is an evidence-based register of in vitro diagnostics (IVD) that supports countries to make national #diagnostic choices. This year’s list includes two firsts: Inclusion of three tests for #hepatitis E virus (HEV), including a rapid test to aid in the #diagnosis and surveillance of HEV infection; and #Advice to include personal use #glucose #monitoring devices along with the medical recommendations for #diabetes already in existence................." - https://lnkd.in/dXbCbvzq

New and upcoming glaucoma procedures … a masterclass on lid margin disease … a case-based MIGS program | These 3 ASCRS Satellite CME programs are all online and complimentary https://bit.ly/3CaQH8O

Clinical gut permeability assessment in Crohn’s Disease Patients using relmapirazin (MB-102) MediBeacon fluorophore technology has been published in GastroHep Advances. https://bit.ly/3OY6Bul

At HI NENC we have developed tried and tested cardiovascular disease prevention resources, to support the spread of innovation and best practice in primary care. 💭 In this blog, hear from pharmacists from North Cumbria, Nicola Sumbler and Jennifer Nellis. The two pharmacists share their approach to lipid optimisation, to improve patient outcomes and support QOF targets. Read here ➡️ https://bit.ly/3vxLo3H #ZeroCVD #CVD

Another great application for relmapirazin (MB-102) MediBeacon fluorophore technology.

Exciting News in the World of Post-COVID Research! 🚀 Delve into the latest findings on the prothrombotic state of Post-COVID Syndrome patients and discover the groundbreaking insights that could pave the way for better treatment options. 👩🔬🧪 #COVIDResearch #MedicalAdvancements #HealthcareInnovation" https://lnkd.in/etKekyZr

Join us in this upcoming webinar to discuss the importance of early detection of peripheral artery disease in optimizing goal-directed medical treatment: 📅 Tuesday, June 18, 2024 🕐 1 - 2 pm EST 🔗 REGISTER: https://hubs.li/Q02z4bxF0 Risk factor management and targeted appropriate interventions prevent disease progression and improve outcomes. Through a review of case examples, speakers will illustrate the positive impact of volume plethysmography-based PAD detection at the point of care and multidisciplinary coordinated care on patient outcomes.

Patients with compromised immune systems face unique challenges when dealing with onychomycosis. Let's explore insights from Dr. Emily Johnson, an experienced immunologist on addressing onychomycosis in these particular patients. Early Detection and Diagnosis: Prompt identification of onychomycosis symptoms is crucial in patients with compromised immune systems. Collaborative Approach: Collaboration between foot care professionals and immunologists is essential for comprehensive treatment plans. Tailored Treatment Options: Customized treatments, considering potential interactions with immunosuppressive drugs, are necessary. Preventive Measures: Educating patients about foot hygiene and avoiding high-risk environments is vital. #CompromisedImmuneSystems #ImmunologistInsights

Explore our new report shedding light on the complexities of rare disease patient recruitment. 🌟 From addressing participant scarcity to overcoming engagement barriers, we present strategic solutions to reshape your approach to these trials. Download to learn more.👇 https://lnkd.in/ex3hFbVy #ClinicalTrials #PrecisionMedicine #RareDisease